Use and Characteristics of Antipsychotic/Methylphenidate Combination Therapy in Children and Adolescents with a Diagnosis of Attention-Deficit/Hyperactivity Disorder

Journal of Child and Adolescent Psychopharmacology
Oliver ScholleOliver Riedel

Abstract

Children and adolescents with attention-deficit/hyperactivity disorder (ADHD) frequently have comorbidities that are potential indications for antipsychotics (APs). Some studies have suggested that the combined use of methylphenidate (MPH) and APs is increasing in this population group. Longitudinal analyses and in-depth investigations on the substance level are lacking. This study aimed to estimate the cumulative proportion of concomitant AP/MPH use in children and adolescents with ADHD over a follow-up of up to 9 years and to describe patient characteristics stratified by specific AP drug. Based on claims data, concomitant AP/MPH use was identified among 67,595 children and adolescents with ADHD starting MPH treatment between 2005 and 2013. Characteristics and diagnoses-including those indicating appropriateness of AP use according to approved indications and/or guidelines-were examined at the time of first AP/MPH combination therapy. In addition, subsequent use of AP/MPH combination therapy was evaluated. The cumulative proportion of individuals with any AP/MPH combination therapy rose to over 6% within 9 years after initiating MPH. The most frequent APs first used in combination with MPH were risperidone (72%), pipamperone ...Continue Reading

References

Aug 15, 2001·Journal of the American Academy of Child and Adolescent Psychiatry·D ThiruchelvamR J Schachar
Sep 7, 2002·Mental Retardation and Developmental Disabilities Research Reviews·Andrew S RowlandAnn J Abramowitz
Jan 25, 2003·Journal of the American Academy of Child and Adolescent Psychiatry·Elizabeth PappadopulosPeter S Jensen
Mar 4, 2003·The American Journal of Psychiatry·Daniel J SaferSusan DosReis
Dec 9, 2003·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Stan KutcherSam Tyano
Aug 24, 2004·European Child & Adolescent Psychiatry·Eric TaylorAlessandro Zuddas
May 3, 2005·Journal of Clinical Epidemiology·Sebastian Schneeweiss, Jerry Avorn
May 25, 2006·Journal of the American Academy of Child and Adolescent Psychiatry·Steven R PliszkaUNKNOWN TEXAS CONSENSUS CONFERENCE PANEL ON PHARMACOTHERAPY OF CHILDHOOD ATTENTION DEFICIT HYPERACTIVITY DISORDER
Dec 2, 2008·Neuropsychiatric Disease and Treatment·Roberto Canitano, Valeria Scandurra
Sep 22, 2010·Journal of the American Academy of Child and Adolescent Psychiatry·Jonathan S ComerRamin Mojtabai
Mar 30, 2011·European Child & Adolescent Psychiatry·Veit RoessnerUNKNOWN ESSTS Guidelines Group
Jun 26, 2012·Neuropharmacology·Veit RoessnerAlexander Münchau
Dec 18, 2013·Journal of the American Academy of Child and Adolescent Psychiatry·Michael G AmanRobert L Findling
Jun 20, 2014·Attention Deficit and Hyperactivity Disorders·Christina Mohr Jensen, Hans-Christoph Steinhausen
Feb 5, 2015·Journal of Child Psychology and Psychiatry, and Allied Disciplines·Guilherme V PolanczykLuis A Rohde
Jan 1, 2015·Nature Reviews. Disease Primers·Stephen V FaraoneBarbara Franke

❮ Previous
Next ❯

Citations

Mar 5, 2019·European Child & Adolescent Psychiatry·Nir MadjarGal Shoval
Jul 24, 2020·European Child & Adolescent Psychiatry·Elin E KimlandAnastasia N Iliadou
Jun 1, 2021·Community Mental Health Journal·Jennifer L McLarenJoAnna K Leyenaar
Aug 3, 2021·Progress in Neuro-psychopharmacology & Biological Psychiatry·Mathieu Di MiceliBenjamin Gronier
Oct 8, 2021·Journal of Child and Adolescent Psychopharmacology·Miika VuoriLeena K Saastamoinen

❮ Previous
Next ❯

Software Mentioned

SAS
GePaRD

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.